PGP and cancer: For instance, administration of dofequidar, a P-gp inhibitor, with anti-cancer drugs such as cyclophosphamide, doxorubicin (Dox) and fluorouracil to patients with advanced or recurrent breast cancer, increased progression-free survival days from 241 (without P-gp inhibitor) to 366 [122].